1. Home
  2. KPTI vs UFI Comparison

KPTI vs UFI Comparison

Compare KPTI & UFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • UFI
  • Stock Information
  • Founded
  • KPTI 2008
  • UFI 1969
  • Country
  • KPTI United States
  • UFI United States
  • Employees
  • KPTI N/A
  • UFI N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • UFI Textiles
  • Sector
  • KPTI Health Care
  • UFI Consumer Discretionary
  • Exchange
  • KPTI Nasdaq
  • UFI Nasdaq
  • Market Cap
  • KPTI 121.2M
  • UFI 123.0M
  • IPO Year
  • KPTI 2013
  • UFI N/A
  • Fundamental
  • Price
  • KPTI $0.86
  • UFI $6.93
  • Analyst Decision
  • KPTI Strong Buy
  • UFI
  • Analyst Count
  • KPTI 4
  • UFI 0
  • Target Price
  • KPTI $5.00
  • UFI N/A
  • AVG Volume (30 Days)
  • KPTI 886.0K
  • UFI 56.9K
  • Earning Date
  • KPTI 10-31-2024
  • UFI 10-30-2024
  • Dividend Yield
  • KPTI N/A
  • UFI N/A
  • EPS Growth
  • KPTI N/A
  • UFI N/A
  • EPS
  • KPTI N/A
  • UFI N/A
  • Revenue
  • KPTI $145,668,000.00
  • UFI $582,209,000.00
  • Revenue This Year
  • KPTI $6.41
  • UFI $16.88
  • Revenue Next Year
  • KPTI $11.85
  • UFI $3.10
  • P/E Ratio
  • KPTI N/A
  • UFI N/A
  • Revenue Growth
  • KPTI N/A
  • UFI N/A
  • 52 Week Low
  • KPTI $0.62
  • UFI $5.41
  • 52 Week High
  • KPTI $1.95
  • UFI $7.91
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 58.15
  • UFI 51.53
  • Support Level
  • KPTI $0.82
  • UFI $6.64
  • Resistance Level
  • KPTI $0.94
  • UFI $7.04
  • Average True Range (ATR)
  • KPTI 0.07
  • UFI 0.30
  • MACD
  • KPTI 0.01
  • UFI -0.05
  • Stochastic Oscillator
  • KPTI 68.90
  • UFI 48.06

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About UFI Unifi Inc. New

Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.

Share on Social Networks: